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Abstract
Background: Estimates of relative efficacy between alternative treatments are crucial for decision making in health
care. When sufficient head to head evidence is not available Bayesian mixed treatment comparison models provide a
powerful methodology to obtain such estimates. While models can be fit to a broad range of efficacy measures, this
paper illustrates the advantages of using continuous outcome measures compared to binary outcome measures.
Methods: Using a case study in rheumatoid arthritis a Bayesian mixed treatment comparison model is fit to estimate
the relative efficacy of five anti-TNF agents currently licensed in Europe. The model is fit for the continuous HAQ
improvement outcome measure and a binary version thereof as well as for the binary ACR response measure and the
underlying continuous effect. Results are compared regarding their power to detect differences between treatments.
Results: Sixteen randomized controlled trials were included for the analysis. For both analyses, based on the HAQ
improvement as well as based on the ACR response, differences between treatments detected by the binary outcome
measures are subsets of the differences detected by the underlying continuous effects.
Conclusions: The information lost when transforming continuous data into a binary response measure translates
into a loss of power to detect differences between treatments in mixed treatment comparison models. Binary
outcome measures are therefore less sensitive to change than continuous measures. Furthermore the choice of
cut-off point to construct the binary measure also impacts the relative efficacy estimates.
Keywords: Bayesian mixed treatment comparison models, Rheumatoid arthritis, Anti-TNF agents
Background
Meta-analysis has developed to be a widely used tool
to combine trials evaluating the same intervention. This
allows more powerful conclusions when a single study
group is too small, and it fits naturally in the Bayesian
framework where the inclusion of all available evidence
into an analysis is anticipated [1]. A natural extension of
a meta-analysis is a mixed treatment comparison (MTC)
where more than two treatments are compared in a net-
work of evidence. While direct evidence is preferable it
is often not available due to ethical or financial reasons
and MTC models provide a powerful tool to estimate rel-
ative efficacy among treatments which are not directly
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compared in a trial. A Bayesian approach to indirect com-
parison allows the inclusion of a wide range of evidence
and is flexible to deal with increasingly complex evidence
structures [2].
The variance of an indirect comparison is typically
larger than the variance of a comparable direct compari-
son; the variance increases with every indirect link in the
chain. It is therefore crucial to make the greatest use of
available data.
Using a case study in rheumatoid arthritis this paper
presents a MTC model on a range of efficacy measures
illustrating the increased power of continuous outcome
measures in such models compared to using binary mea-
sures. For the presentation of the analysis we follow the
checklist suggested by Spiegelhalter et al. [3].
© 2012 Schmitz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
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Dichotomized outcomemeasures
Dichotomized outcome measures are widespread in med-
ical research. The perceived advantage of simplicity in the
interpretation comes at a cost, however [4]. The loss of
information results in a loss of power to detect relation-
ships, furthermore the type I error rate may be inflated [5]
and there is a risk of underestimating the variance param-
eter. These issues have been discussed in the literature
relating to a number statistical analyses [6-9].
In this work we demonstrate the consequences of
dichotomized outcome measures in the context of MTC
modelling. It has been pointed out that dichotomization
can be used when designing trials to quantify a treatment
effect [10,11]. This is the primary aim of many clinical tri-
als aiming for license approval. The anticipated efficacy
level is taken as a cut-off point and results allow a straight-
forward interpretation. Pharmacoeconomic assessments
of healthcare interventions are now a formal compo-
nent of decision making in many countries [12]. Evidence
syntheses typically rely on published clinical trials to esti-
mate the relative efficacy among alternative agents to
inform decision making. This has created an additional
use of clinical trials demonstrating treatment efficacy, for
which dichotomized measures suffer from disadvantages
compared to the underlying continuous effect measure.
The loss of power due to dichotomization adds to the
increased variance in indirect comparisons. This is espe-
cially problematic for MTCs (vs. pairwise meta-analysis),
since they typically have large standard errors due to the
indirect nature of the comparison.
The intervention
Rheumatoid arthritis (RA) is a chronic, progressive and
disabling auto-immune disease, causing swelling and
damaging cartilage and bone around the joints. Any joint
may be affected but it is commonly the hands, feet and
wrists. Common symptoms are joint swelling, pain, morn-
ing joint stiffness, poor sleep, fatigue and weight loss
[13].
Over the past decade, enhanced understanding of the
molecular pathogenesis has led to the development of
biologic agents that target specific parts of the immune
system. These innovative treatments have altered the path
and face of RA and outcomes for patients and society.
Tumour necrosis factor alpha antagonists (anti-TNF-α)
are the first of the biologic treatment groups used in
RA. There are currently five anti-TNF agents licensed
for RA in Europe; adalimumab, certolizumab, etaner-
cept, golimumab and infliximab. All of these agents have
demonstrated considerable efficacy in placebo controlled
randomized controlled trials (RCTs) in patients who
have had an inadequate response to conventional Dis-
ease Modifying Anti-Rheumatic Drugs (DMARDs) such
as methotrexate (MTX) or sulphasalazine.
While there is a wealth of RCT evidence available for
these agents compared to either placebo or conventional
DMARDs, there are currently very limited head-to-head
RCTs of anti-TNF agents. Despite this, some estimate
of relative efficacy in order to inform choice of agent
is needed. In the absence of head-to-head trials of rel-
evant comparators, it is necessary to combine evidence
from placebo controlled trials of different treatments and
thereby derive an estimate of effect of one treatment
against another. This can be broadly termed as mixed
treatment comparison (MTC), an extension of meta-
analysis. Different methodologies have been described for
MTC; one such method uses Bayesian hierarchical mod-
els. Such models provide more flexibility than classical
methods to include more data and handle more complex
modelling structures [14].
Aim of the analysis
The aim of this analysis is to demonstrate the advan-
tage of using continuous measures in MTC models com-
pared to using binary measures. In the present analysis a
MTCmodel is fitted to estimate all pair-wise comparisons
among the five TNF-α inhibitors and placebo for a range
of outcome measures.
Nixon et al. [15] have developed a MTC model to fit the
binomial American College of Rheumatology (ACR) out-
come measure; it is possible to include trials with multiple
treatment arms and to adjust for study level covariates.
Jansen et al. [16] have presented a MTC model on the
outcome of the Health Assessment Questionnaire (HAQ),
which is measured on a continuous scale. However, they
did not allow for multiple treatment arms or the inclusion
of baseline characteristics. The present analysis extends
Jansen’s methods to allow for these.
While binary measures are useful for demonstrating a
certain level of efficacy in clinical trials, we will show that
the loss of information when changing from the under-
lying continuous scale to the binary outcome measure
results in a loss of power to detect differences between
treatments in MTC analyses.
Fitting models for a continuous improvement measure
and a discretised version thereof as well as for binary
outcome measures and a continuous version of these
illustrates the enhanced power to detect differences of
continuous measures compared to binary measures.
The chosen outcome measures are based on the ACR
criteria and the HAQ score. Details are described in the
next section.
Efficacy Measures
In order to estimate the relative efficacy between treat-
ments one has to decide on a measure of disease activity
and improvement. Commonly used measures in RA are
the ACR criteria, the Disease Activity Score (DAS) and the
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HAQ score. Table 1 summarises the different measures of
improvement. While other measures exist, they are out-
side the scope of this paper and are discussed elsewhere
[17].
The ACR response criteria is a binary combinationmea-
sure including the number of tender and swollen joints,
patient’s global assessment, physician’s global assessment,
pain, degree of disability and level of acute-phase reac-
tant. In order to achieve an ACR 20, ACR 50 or ACR 70
result, an improvement of 20%, 50% or 70% respectively is
required in the swollen and tender joint counts as well as
in 3 of the 5 remaining dimensions [18,19].
Continuous measures based on the ACR criteria have
been introduced including the meanACR and the ACR
hybrid measure [20]. The meanACR measures the mean
% improvement in the seven ACR core set measures. The
ACR hybrid measure combines the ACR 20, ACR 50 and
ACR 70 with the ACRmean. A patient’s ACR hybrid out-
come is the same as the ACRmean, but restricted by his
binary ACR response. For example, the outcome for a
patient who is an ACR 20 responder, but not an ACR 50
responder is restricted to the interval [0.2, 0.5).
The HAQ score represents the result of a self-report
questionnaire in which patients rate their ability to per-
form daily life activities such as washing one’s hair or
getting in and out of a car. Values range from 0 to 3 in steps
of 0.125, where high values indicate a more severe disease
status. The improvement in HAQ score is measured on a
continuous scale.
For the purpose of demonstrating the enhanced power
of continuous measures in MTC models we have defined
a discretised version of the HAQ score: HAQ 20 and HAQ
50. They are defined analogously to ACR 20 and ACR
50. A patient achieves a HAQ 20 outcome, if his HAQ
score has improved by at least 20%; a 50% improvement is
required for HAQ 50.
The DAS28 score is a combination measure on a con-
tinuous scale from 0 to 10 incorporating swollen joint
count (swollen28), tender joint count (tender28) (out of 28
defined joints), an evaluation of the patients general health
Table 1 Measuring improvement in RA: ACR (American
College of Rheumatology); HAQ (Health Assessment
Questionnaire); DAS28 (Disease Activity Score)
ACR HAQ DAS28
continuous meanACR HAQ %-improvement DAS28
ACRhybrid
binary ACR 20 HAQ 20∗
ACR 50 HAQ 50∗
ACR 70
∗Note: HAQ 20 and HAQ 50 are not validated response measures, they have
been created here for the purpose of illustrating the loss of power in binary vs.
continuous measures.
(GH) and the erythrocyte sedimentation rate (ESR). The
score is obtained using the formula [21]:
DAS28 = 0.56∗√tender28 + 0.28 ∗ √swollen28
+ 0.70 ∗ ln(ESR) + 0.014 ∗ GH (1)
Methods
Data
A systematic literature review following the PRISMA
method [22] was performed to identify trials meeting
our inclusion criteria. The search included published
studies up to and including October 2010 in PubMed,
Embase and the Cochrane Database. Rheumatological
inflammatory diseases other than RA, such as ankylos-
ing spondylitis, psoriatic arthritis and connective tissue
diseases were excluded from the search. The inclusion cri-
teria were randomised controlled trials (RCTs), patients
with established RAwho have had an inadequate response
to methotrexate (MTX) and who have been treated for
at least 24 weeks (where 24 week data were not avail-
able, data within 6 weeks either before or after 24 weeks
were used). Both monotherapy and combination therapy
were included with an explicit term in the statistical model
allowing for the additional effect of MTX. More details on
the selection process can be found elsewhere [23].
The outcome measures chosen were those described
in the previous section based on the ACR criteria, the
HAQ score and the DAS28. Unfortunately the DAS28 was
reported in too few trials to fit a MTC model (DAS28 was
only reported in 6 trials, not representing each of the treat-
ments). The total number of responders achieving ACR
20, ACR 50 and ACR 70 response and the mean improve-
ment and standard deviations (SDs) for the continuous
HAQ measure were extracted. Authors were contacted in
cases where the required data were not reported. Where
no access to the missing data was provided, the follow-
ing methodology was applied: in cases where the mean
was not reported, the median was used; in the absence
of SDs, interquartile ranges (IQRs) were used to estimate
SDs using a normal approximation, and, in the remain-
ing cases, the maximum of clinical trial SDs was used.
The doses of biological agents included are those included
in the RCTs. Demographic data including age, gender,
mean disease duration, baseline HAQ score and number
of previous DMARDs were recorded.
Statistical Model
A Bayesian MTC model is fitted to the data for each of
the outcome measures of interest (HAQ, HAQ 20, HAQ
50, ACR 20, ACR 50, ACR 70 and ACRcont). Such mod-
els simultaneously perform indirect comparisons between
treatments that are not directly compared and allow esti-
mation of all pair-wise comparisons. A network diagram
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represents the underlying evidence structure of suchmod-
els. Figure 1 shows the generalisation of meta-analysis
to the simplest case of an indirect comparison. Network
diagrams consist of nodes representing the interventions
included in the analysis and edges between nodes identify
interventions which are directly compared in one or more
trials. Dotted lines are used to indicate the indirect com-
parison of interest. For simplicity, these are often omitted
when all comparisons for which no direct evidence is
available is of interest.
In a simple meta-analysis evidence from a range of tri-
als comparing the same two interventions A and B is
combined yielding an overall A vs. B estimate (see evi-
dence network in Figure 1(a)). The underlying method-
ology is well explored and used extensively in practice.
The simplest case of a MTC occurs when this situation is
extended to include a third intervention, drug C, which
has also been compared to drug A in clinical trials (see
Figure 1(b)). MTC modelling assumes that the combined
evidence from A vs. B and A vs. C trials contains some
information about the relative efficacy of B vs. C; in par-
ticular B vs. C is assumed to be the difference between A
vs. B and A vs. C (see Figure 1(c)). MTC models can be
fitted for all underlying evidence structures as long as the
network diagram is connected. Combining evidence this
way evokes the assumption of treatment exchangeability,
a similarity assumption among the trials. The effect of B
in the A vs. B trials is assumed to occur if C was replaced
by B in the A vs. C trials. Unfortunately this assump-
tion can only be tested in networks of closed loop design,
where consistencymeasures can be obtained; methods are
described elsewhere [24]. When this is not the case, great
care has to be taken in selecting the trials for the analysis.
All models can be fitted in a Bayesian or in a classical
framework. The Bayesian approach to MTC modelling is
the most flexible, allowing the inclusion of a wide range of
data and borrowing strength across the network ensures
the optimal use of the data. Details on classical methods
can be found elsewhere [25,26]. This analysis focuses on
the Bayesian approach only.
In the remainder of this section the mathematical mod-
els for binary and continuous outcome measures are
described beginning with simple meta-analytic models
which are then extended to MTC models including base-
line characteristics and other assumptions necessary for
the RA model.
SimpleMeta Analysis
In a simple meta analysis only two interventions are com-
pared; evidence of a number of trials is combined to
get an overall estimate for the difference in effect. The
continuous mathematical model is the following [16]:
⎧⎪⎨
⎪⎩
i ∼ N(δi, σ 2i )
δi ∼ N(d, σ 2δ )
d ∼[−,−] σδ ∼[−,−]
(2)
i is the observed relative treatment effect in study i;
σi the associated sampling error; i = 1, . . .N , where
N is the number of trials included in the analysis. The
model assumes random effects, meaning the study specific
true effects δi are drawn from a normal distribution with
mean d and between trial variance parameter σ 2δ . Prior
distributions need to be specified for the basic parame-
ter d and the between trial standard deviation σδ . The
choice of prior distribution is discussed in section “Prior
distributions”, in this section we simply indicate which
parameters require a prior distribution.
The binary counterpart to calculate odds ratios can be
formulated as follows:
⎧⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎩
r.ci ∼ Bin(n.ci, p.ci); r.ti ∼ Bin(n.ti, p.ti)
logit(p.ci) = μi
logit(p.ti) = μi + δi
δi ∼ N(d, σ 2δ )
d ∼[−,−] μi ∼[−,−] σδ ∼[−,−]
(3)
A binomial likelihood is assumed for the number of
patients and number of responders in control arm and
treatment arm of each study; n.ci, n.ti, r.ci, r.ti respectively.
The model calculates log odds ratios (LORs) for each
study, δi, for which random effects are assumed yielding an
a b c
Figure 1 Generalisation frommeta-analysis to mixed treatment comparison.
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overall log odds ratio estimate d and a between trial stan-
dard deviation σδ . Prior distributions need to be assigned
to d, the logits in the control group μi and σδ .
Figure 2 shows the directed acyclic graph (DAG) for (a)
the continuous and (b) the binary meta-analysis model.
Extension toMTC
The models described in (2) and (3) for a simple meta
analysis can be extended to a MTC model, which allows
the estimation of relative efficacy among more than two
interventions [14,16]. Mathematically this means the con-
tinuous model in equation (2) changes to:
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
i ∼ N(δi,k,P , σ 2i )
δi,k,P ∼ N(dk,P , σ 2δ )
ICk,l = dk,P − dl,P k = l
dk,P ∼[−,−] σδ ∼[−,−]
(4)
As before i refers to the observed relative treatment
effects of the comparison in study i with respective mea-
sure of variability σi. k and l indicate the anti-TNF agent
evaluated in the trials; 1 indicates adalimumab, 2 inflix-
imab, 3 etanercept, 4 golimumab and 5 certolizumab. The
baseline treatment is placebo, indicated by P. Assuming
random effects, the study specific true effects are drawn
from a normal distribution with a mean specific to the
comparison; i.e. the effects of all trials comparing the same
two interventions are drawn from the same normal distri-
bution. The between trial variance parameter is assumed
to be the same for all comparisons. Each comparison of
drug k versus drug l, ICk,l, can be written in terms of basic
parameters dk,P . Prior distributions are required for basic
parameters and between trial standard deviation σδ .
For the binary outcome measures the model in equation
(3) extends to:
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
r.ci ∼ Bin(n.ci, p.ci); r.ti ∼ Bin(n.ti, p.ti)
logit(p.ci) = μi
logit(p.ti) = μi + δi,k,P
δi,k,P ∼ N(dk,P , σ 2δ )
ICk,l = dk,P − dl,P k = l
dk,P ∼[−,−] μi ∼[−,−] σδ ∼[−,−]
(5)
Again n.ci, n.ti, r.ci and r.ti refer to the number of patients
and number of responders in the control and treatment
arm of each study. The model calculates LORs δi,k,P for
each study, which are combined assuming random effects
with a common mean for each baseline comparison dk,P .
The between trial SD is assumed to be the same for all
drugs. All other comparisons ICk,l can be estimated from
the baseline parameters. Prior distributions need to be
defined for dk,P , μi and σδ .
Further extensions
For the use of the model for RA data three more adjust-
ments have to be made. We want to allow for more
than one treatment arm per study; adjustments have to
be made for the concurrent treatment with MTX. Fur-
thermore, we would like to model the improvement rel-
ative to baseline disease activity, since disease activity at
baseline influences the effectiveness of the intervention
[27]. Also, the results of this analysis provide the basis
for an economic analysis, which requires the percentage
improvement in HAQ score as input parameters.
A step by step approach is taken to include these
assumptions into the model described in (4) for the con-
tinuous case and (5) for the binomial case.
As a first step the allowance for multiple treatment arms
is included. Let index j refer to treatment arm j (j =
(a) (b)
Figure 2 DAG for (a) continuous and (b) binary meta analysis model.
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1, . . . ,M, where M is the total number of treatment arms
in the analysis) and s(j) refers to the study of treatment
arm j. The continuous mathematical model then takes the
following form:
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
j = .tj − .cs(j)
j ∼ N(δj,k,P , σ 2j )
δj,k,P = δs(j),k,P
δs(j),k,P ∼ N(dk,P , σ 2δ )
ICk,l = dk,P − dl,P k = l
dk,P ∼[−,−] σδ ∼[−,−]
(6)
For each treatment arm the observed effect relative to
the comparator arm is calculated as j, which as before
has a normal distribution with measure of variability σj.
The model makes the assumptions that effects in treat-
ment arms of the same study are constant, we therefore
assume fixed effects for within study effects. This assump-
tion is described in line 3 of equation (6). Between trials
we assume random effects, as before and each compari-
son ICk,l can be written in terms of basic parameters dk,P .
Prior distribution need to be defined for basic parameters
and between trial standard deviation σδ .
This model takes the following form for binary outcome
measures:
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
r.cs(j) ∼ Bin(n.cs(j), p.cs(j)); r.tj ∼ Bin(n.tj, p.tj)
logit(p.cs(j)) = μs(j)
logit(p.tj) = μs(j) + δj,k,P
δj,k,P = δs(j),k,P
δs(j),k,P ∼ N(dk,P , σ 2δ )
ICk,l = dk,P − dl,P k = l
dk,P ∼[−,−] μs(j) ∼[−,−] σδ ∼[−,−]
(7)
Changes from equation (5) to (7) are analogous to changes
in the continuous case. A LOR δj,k,P is obtained for each
treatment arm; treatment arms of the same study are
assumed to estimate the same treatment effect, hence line
4 in equation (7). Everything else remains the same.
In a next step we will extend the model to allow for
the concurrent treatment with MTX. The effect due to
MTX is assumed to be additive, meaning the relative effect
between two arms where no MTX is given is the same as
the relative effect between two arms where MTX is given
in both arms:
(A + MTX) vs. (B + MTX) = A vs. B (8)
The continuous model takes the following form:⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
j = .tj − .cs(j)
j ∼ N(δj,k,P , σ 2j )
δj,k,P = αs(j),k,P + βs(j)(I.tj − I.cs(j))
αs(j),k,P ∼ N(ak,P , σ 2α )
βs(j) = b
ICk,l = ak,P − al,P k = l
ak,P ∼[−,−] b ∼[−,−]
σα ∼[−,−]
(9)
The difference to the previous model described in
equation (6) is the splitting of treatment effect δj,k,P into
a part representing the effect due to the drug of interest
(in the RA case the anti-TNF effect) αs(j),k,P and a part
explaining the effect which is due to the concurrent treat-
ment withMTX, βs(j). I.ti and I.cs(i) are indicator variables
indicating whetherMTXwas given in treatment and com-
parator group. By multiplying the βs(i) with the difference
of the indicator the assumptions of an additive effect as
explained above is implemented. In this way, only treat-
ment arms, where MTX is given in either the treatment
arm or in the respective control arm inform parameter
βs(j). As previously the effect in arms of the same study is
assumed constant, hence βj = βs(j) and αj,k,P = αs(j),k,P
(this line has been omitted in the equation for simplicity;
the effect is incorporated in line 3 of equation 9). Between
trials random effects are assumed for αs(j),k,P and fixed
effects for βs(j). One could just as well assume random
effects for βs(j); but the RA data does not provide suffi-
cient evidence to inform a between trial variability for b.
All comparisons ICk,l can be expressed in terms of basic
parameters ak,P . Prior distributions need to be specified
for the basic parameters, for b and for the between trial
standard deviation σα . The binary version of this model is
mathematically described as follows:⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
r.cs(j) ∼ Bin(n.cs(j), p.cs(j)); r.ti ∼ Bin(n.tj, p.tj)
logit(p.cs(j)) = μs(j) + βs(j) ∗ I.cs(j)
logit(p.tj) = μs(j) + βs(j) ∗ I.ts(j) + αs(j),k,P
αs(j),k,P ∼ N(ak,P , σ 2α )
βs(j) = b
ICk,l = ak,P − al,P k = l
ak,P ∼[−,−] μs(j) ∼[−,−] b ∼[−,−]
σα ∼[−,−]
(10)
Again, changes follow analogously to changes made in
the continuous case. In a last step we want to extend
the model such that the drug effect αs(j),k,P depends on
baseline disease activity. To model relative percentage
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improvement α is modelled as a multiplier to the HAQ
score at baseline λi. All other aspects of model (9) remain
unchanged.
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
j = .tj − .cs(j)
j ∼ N(δj,k,P , σ 2j )
δj,k,P = αs(j),k,P ∗ λj + βs(j)(I.tj − I.cs(j))
αs(j),k,P ∼ N(ak,P , σ 2α )
βs(i) = b
ICk,l = ak,P − al,P k = l
ak,P ∼[−,−] b ∼[−,−] σα ∼[−,−]
(11)
The binomial measures selected for this study are by defi-
nition relative to baseline disease activity, since the cut-off
between case and no case is a % improvement relative
to baseline. It is therefore not necessary to adjust the
model defined in equation 10 further. For completeness,
we will introduce the concept of meta-regression, which
allows for the adjustment for baseline characteristics in
the analysis. The resulting model is:
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
r.cs(j) ∼ Bin(n.cs(j), p.cs(j)); r.tj ∼ Bin(n.tj, p.tj)
logit(p.cs(j)) = μs(j) + βs(j)∗I.cs(j)
logit(p.tj) = μs(j) + βs(j)∗I.ts(j) + αs(j),k,P + γ ∗λs(j)
αs(j),k,P ∼ N(ak,P , σ 2α )
βs(j) = b
ICk,l = ak,P − al,P k = l
ak,P ∼[−,−] μs(j) ∼[−,−] b ∼[−,−]
σα ∼[−,−] γ ∼[−,−]
(12)
γ refers to the regression parameter for the baseline HAQ
score.
Models described in equations 10 and 11 enable the
estimation of relative efficacy of a number of treatments
while allowing for multiple treatment arms, concurrent
treatment with additional medication and dependence
of treatment effect on baseline disease activity for both
for(j IN 1 : N.t)
for(j IN 1 : N.c) for(i IN 1 : 5)
for(l IN 1 : 5)
for(k IN 1 : 5)
Delta[j]
alpha[j]drug[j]
I.c[j]
I.t[j]
lambda[j]
alpha.m[j]
delta[j]
Delta.c[j]
s[j]
Delta.t[j]
Delta[j]
tau.delta[j] var.delta[j]
sd.delta[j]
beta[j]
sigma
b
tau.a
sigma.sq
a[i]
IC[k,l]
Figure 3 DAG for continuous MTCmodel in equation (11). Square shaped nodes represent constants, oval shaped nodes are either random or
logical. A random dependency between two nodes can be found where a single arrow connects both nodes, a double arrow shows that there is a
logical relationship. Loops are represented by boxes.
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continuous and binary outcome measures. In the contin-
uous case differences in efficacy are estimated; odds ratios
are estimated in the binary case. Using methods by Warn
et al. [28] the model can be modified to calculate other
measures, such as risk ratios.
This model has been developed by Nixon et al. [15] for
the binary case. Figure 3 shows the DAG for the finalMTC
models described by equations (11).
Prior distributions
The models described above require prior distributions
for the baseline treatment effect, for the effect due to
MTX, for the between trial standard deviation and in the
binomial models for the log odds of response in the con-
trol group and the meta-regression parameter. For the
analysis we have chosen vague priors for all of these as
described below. The prior distribution in a Bayesian anal-
ysis represents the knowledge about the parameter prior
to the analysis; in the absence of prior knowledge vague
prior distributions intend to cover a wide area of plausi-
ble values, such that little information is entered into the
analysis. For the treatment effect parameters d in model
(2) and (3), dk,P in models (4)-(7), for ak,P and b in (9) -
(12), for the log odds in the control group of the binomial
models μi as well as for γ we have chosen a normal distri-
bution centred at no treatment effect 0 with a very large
variance:
d ∼ N(0, 10000)
dk,P ∼ N(0, 10000)
a ∼ N(0, 10000)
(13)
b ∼ N(0, 10000)
μi ∼ N(0, 10000)
γ ∼ N(0, 10000)
The same prior can be used for both continuous and
binary models, since the risk difference and the log odds
ratios take values on the real line where 0 represents no
difference. The priors do not favour any of the drugs and
allows for a wide range of likely values in favour for each.
This is a widely used vague prior on treatment effects.
A uniform distribution was chosen for the between
trial standard deviation parameter σδ/α , as proposed by
Gelman [29].
σδ/α ∼ dunif (0, 2) (14)
To test whether the range of the uniform prior was cho-
sen appropriately the analysis has been rerun using wider
ranges (dunif (0, 5) and dunif (0, 7)) and estimates did not
change.
Computation/ Software
TheMTCmodels were fitted inWinBUGs, a MCMC soft-
ware using Gibbs sampling [30]. The DAG in Figure 3 is
drawn in WinBUGs. Square shaped nodes represent con-
stants; oval shaped nodes are either random or logical.
A random dependency between two nodes can be found
where a single arrow connects both nodes, a double arrow
shows that there is a logical relationship. Loops are rep-
resented by boxes. The complete code and input data is
Figure 4 Network diagram for RA analysis. Edges are labelled with the number of studies and the total number of patients included in these
studies. Numbers in square brackets refer to HAQ evidences where this differs from ACR evidence.
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Table 2 Trial Data: Number of patients N; improvement in HAQ scoreHAQ; number of ACR20, ACR50, ACR70
responders; HAQ score at baseline HAQbase; + indicates additional treatment with MTX
Trial Arm N HAQ(SD) ACR20 ACR50 ACR70 HAQbase
Weinblatt et al. [31] P+ 62 0.27 (0.6) 9 5 3 1.64
Ada+ 69 0.54 (0.6) 33 22 7 1.52
Ada+ 67 0.62 (0.6) 45 37 18 1.55
Ada+ 73 0.59 (0.5) 48 31 14 1.55
Keystone et al. [32] P+ 200 0.24 (0.5) 59 19 5 1.45
Ada+ 207 0.56 (0.5) 131 81 43 1.44
Ada+ 212 0.60 (0.5) 129 87 37 1.48
Van de Putte et al. [33] P 110 0.07 (0.5) 21 9 2 1.88
Ada 112 0.39 (0.6) 44 23 11 1.88
Ada 106 0.29 (0.6) 38 20 9 1.88
Ada 103 0.49 (0.5) 55 36 19 1.84
Ada 113 0.38 (0.6) 52 25 14 1.83
Miyasaka [34] P 87 -0.1 (0.6) 12 5 1 1.39
Ada 87 0.2 (0.5) 25 14 9 1.57
Ada 91 0.2 (0.6) 40 22 11 1.64
Ada 87 0.4 (0.6) 44 28 13 1.77
Kim at el. [35] P+ 63 0.2 (0.5) 23 9 5 1.3
Ada+ 65 0.5 (0.6) 40 28 14 1.4
Maini et al. [36] P+ 88 0.3 (0.5)‡ 18 7 0 1.8
Inf+ 86 0.3 (0.5)‡ 45 22 7 1.8
Inf+ 86 0.5 (0.5)‡ 47 25 9 1.8
Inf+ 87 0.5 (0.6)‡ 51 26 15 1.8
Inf+ 81 0.4 (0.5)‡ 49 21 9 1.5
Westhoven et al.[37] P+ 363 - 87 33 16 1.5
Inf+ 360 - 199 110 48 1.5
Inf+ 361 - 205 119 54 1.5
Zhang et al. [38] P+ 86 0.45 (-) 42 22 12 1.6
Inf+ 87 0.76 (-) 66 38 20 1.6
Schiff et al. [39] P+ 110 - 49 22 10 1.8
Inf+ 165 - 98 61 40 1.7
Moreland et al. [40] P 80 0.03 (-) 9 4 1 1.7
Eta 76 0.58 (-) 39 18 7 1.7
Eta 78 0.62 (-) 46 31 12 1.6
Weinblatt et al. [41] P+ 30 0.4 (-) 8 1 0 1.5
Eta+ 59 0.7 (-) 42 23 9 1.5
Keystone et al. [42] P+ 133 0.13red* (0.4)† 37 18 7 1.25*
Gol 133 0.13* (0.7)† 47 26 15 1.38*
Gol+ 89 0.38* (0.5)† 53 33 18 1.38*
Gol+ 89 0.5* (0.5)† 53 29 16 1.38*
Kay et al. [43] P+ 35 - 13 2 0 1.3
Gol+ 35 - 21 13 3 1.7
Gol+ 34 - 19 10 6 1.8
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Table 2 Trial Data: Number of patients N; improvement in HAQ scoreHAQ; number of ACR20, ACR50, ACR70
responders; HAQ score at baseline HAQbase; + indicates additional treatment with MTX (Continued)
Keystone et al. [44] P+ 199 0.18 (-) 27 15 6 1.7
Cert+ 393 0.60 (-) 231 146 84 1.7
Cert+ 390 0.63 (-) 237 156 79 1.7
Smolen et al. [45] P+ 127 0.14 (0.5) 11 4 1 1.6
Cert+ 246 0.5 (0.5) 141 80 39 1.6
Cert+ 246 0.5 (0.5) 142 81 26 1.6
Fleischmann et al. [46] P 109 -0.07 (0.4)‡ 10 4 0 1.6
Cert 111 0.39 (0.7)‡ 51 25 9 1.4
Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo. *Median; † estimated from IQR; ‡ data provided by authors
following request.
provided in Additional file 1. Computational feasability
allowed for a large number of iterations. Each model dis-
carded 50,000 burnin iterations and was run with 100,000
iterations and two chains. Convergence was analysed
using CODA; the effective sample size was checked, and
visual inspection of the autocorrelation and the chains
confirmed convergence.
Results and discussion
Data
The systematic literature review identified sixteen RCTs
meeting our inclusion criteria. Figure 4 shows the net-
work of available evidence. Table 2 summarises the data
extracted from the trials, baseline demographics can be
found in Additional file 2.
The MTC models described previously are fit to the
data; the continuous model for the improvement in HAQ
score and the binary model for the ACR 20, ACR 50 and
ACR 70 outcome measures.
The aim of this paper is to demonstrate the increased
power of continuous outcome measures to detect differ-
ences in MTC models compared to binary measures. To
explore this hypothesis the HAQ score was discretised to a
binary outcome measure and the ACR criteria were trans-
formed into a continuous measure; the resulting measures
were analysed in addition to the trial reported outcome
measures and results compared. The rationale for doing
this was that comparing HAQ and ACR outcomes is
not comparing like with like; they measure quite differ-
ent aspects of disease and additional significant findings
using the HAQ score could be because of this rather than
there being any effect of a continuous vs. a binary out-
come measure. Estimating a discrete version of the HAQ
and a continuous measure of the ACR allows us to com-
pare binary and continuous outcomes while the measure
is kept fixed.
Discretised HAQ: HAQ 20 and HAQ 50
For the purpose of comparing continuous and binary out-
come measures based on the same data, the HAQ 20
and HAQ 50 measures defined previously are estimated
based on the continuous HAQ improvement. These dis-
cretised HAQ outcomes are not validated outcome mea-
sures for RA and are therefore not reported in the
trials.
The trials report mean and standard deviation of HAQ
improvement. The number of HAQ 20 and HAQ 50
responders in each trial arm was estimated as follows. For
each trial arm, the HAQ improvement of 1000 patients
was generated by reference to normal distribution with
mean and SD given from the data in that group. From
these patients the proportion of HAQ 20 and HAQ
50 responders was calculated and applied to the num-
ber of patients in each trial arm. Data is summarised
in Table 3.
Continuous ACR: ACRcont
While the continuous ACR measures were proposed by
the Americal College of Rheumatology [20], they were
not assessed in any of the trials. Therefore a continu-
ous ACR measure ACRcont is generated based on the
ACR 20, ACR 50 and ACR 70 outcomes reported in the
trials. This enables us to compare the outcomes of the
binary measures with those resulting from the continuous
scale. ACRcont takes a value between 0 and 1 represent-
ing the percentage improvement in the dimensions which
are combined for the binary ACR criteria.
The trial data allows the categorisation of patients into
non-responders (group 1) (patients not achieving an ACR
20 response), patients achieving ACR 20 but not ACR
50 response (group 2), patients achieving ACR 50 but
not ACR 70 response (group 3) and ACR 70 respon-
ders (group 4). Assuming a mean ACRcont response
mi for each group of patients these numbers are used
to generate the mean and SD of ACRcont for each
trial arm:
Mean(ACRcont) = 1N
( 4∑
i=1
Ni · mi
)
(15)
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Table 3 Input Data for discretised HAQ score and continuous ACR: Number of patients N; number of HAQ20 and HAQ50
responders; continuous ACR response ACRcont; + indicates additional treatment with MTX
Trial Arm N HAQ20 HAQ50 ACRcont (SD)
Weinblatt et al. [31] P+ 62 30 12 0.08 (0.22)
Ada+ 69 45 24 0.35 (0.20)
Ada+ 67 47 26 0.46 (0.22)
Ada+ 73 52 26 0.42 (0.21)
Keystone et al. [32] P+ 200 95 32 0.13 (0.22)
Ada+ 212 141 81 0.42 (0.21)
Ada+ 207 154 82 0.41 (0.21)
Van de Putte et al. [33] P 110 29 4 0.09 (0.20)
Ada 112 47 16 0.31 (0.19)
Ada 106 60 19 0.30 (0.19)
Ada 103 57 20 0.38 (0.22)
Ada 113 60 21 0.33 (0.20)
Miyasaka [34] P 87 23 8 0.07 (0.17)
Ada 87 37 10 0.28 (0.19)
Ada 91 39 16 0.33 (0.20)
Ada 87 48 18 0.37 (0.21)
Kim et al. [35] P+ 63 28 10 0.18 (0.27)
Ada+ 65 43 24 0.42 (0.22)
Maini et al. [36] P+ 88 40 9 0.09 (0.19)
Inf+ 86 40 12 0.35 (0.19)
Inf+ 86 54 19 0.36 (0.20)
Inf+ 87 52 23 0.38 (0.21)
Inf+ 81 48 20 0.37 (0.19)
Westhoven et al. [37] P+ 363 - - 0.12 (0.23)
Inf+ 360 - - 0.37 (0.20)
Inf+ 361 - - 0.38 (0.21)
Zhang et al. [38] P+ 86 52 28 0.27 (0.31)
Inf+ 87 61 39 0.46 (0.20)
Schiff et al. [39] P+ 110 - - 0.22 (0.29)
Inf+ 165 - - 0.41 (0.22)
Moreland et al. [40] P 80 25 8 0.06 (0.16)
Eta 76 47 26 0.34 (0.19)
Eta 78 53 31 0.40 (0.21)
Weinblatt et al. [41] P+ 30 16 8 0.10 (0.17)
Eta+ 59 45 29 0.43 (0.19)
Keystone et al. [42] P+ 133 49 13 0.14 (0.25)
Gol 133 56 29 0.30 (0.20)
Gol+ 89 51 24 0.40 (0.22)
Gol+ 89 60 31 0.39 (0.21)
Kay et al. [43] P+ 35 - - 0.14 (0.20)
Gol+ 35 - - 0.39 (0.20)
Gol+ 34 - - 0.38 (0.21)
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Table 3 Input Data for discretised HAQ score and continuous ACR: Number of patients N; number of HAQ20 and HAQ50
responders; continuous ACR response ACRcont; + indicates additional treatment with MTX (Continued)
Keystone et al. [44] P+ 199 83 35 0.07 (0.20)
Cert+ 393 263 146 0.40 (0.22)
Cert+ 390 249 137 0.41 (0.22)
Smolen et al. [45] P+ 127 46 10 0.04 (0.14)
Cert+ 246 163 66 0.38 (0.21)
Cert+ 246 155 67 0.38 (0.20)
Fleischmann et al. [46] P 109 19 2 0.04 (0.14)
Cert 111 60 34 0.33 (0.19)
Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo.
where Ni refers to the number of patients in each group
and N =∑4i=1Ni.
sd(ACRcont) = 1N
√√√√ 4∑
i=1
Ni · (mi − Mean(ACRcont))2
(16)
Patient level data from a RA cohort allowed the esti-
mation of mi for the four groups [47]. Mean ACRcont
response can be based on either continuous ACRmeasure
described previously, depending upon which underlying
measure we are trying to recreate. For the main analy-
sis we are using the meanACR measure; results based on
the ACRhybrid are discussed in the sensitivity analysis.
Table 4 summarizes the mean ACRcont responses for the
four groups based on both outcome measures. Improve-
ment in the core sets is measured by a drop in score;
therefore overall improvement is restricted by an upper
bound of 100%. To achieve a symmetric measuring scale
overall worsening has also been restricted to -100% in
each of the criteria, as proposed elsewhere [20].
The patient level estimates are based on patients receiv-
ing biologic treatment; estimates can therefore be applied
to the treatment arms of the studies. Unfortunately no
patient level data representing the control groups is avail-
able to us. Given the lack of further information the
analysis assumes interval midpoints as mean ACRcont
estimates for the control groups. Group 1 is assumed to
have a response in [-1, 0.2), group 2 in [0.2, 0.5), group 3
in [0.5, 0.7) and the response of group 4 lies in [0.7, 1]. The
interval for non responders is very broad covering a wide
Table 4 Mean improvement estimated from patient level
data
group 1 group 2 group 3 group 4
meanACR 0.17 0.41 0.57 0.72
ACRhybrid 0.10 0.41 0.59 0.77
Control Group 0.00 0.35 0.60 0.85
range of extreme values. The baseline analysis therefore
assumes a conservative mean value of 0.00 for this group.
This yields the control group estimates in Table 4. Alter-
native scenarios assuming the samemean response for the
control group as estimated for the treatment group are
analysed in the sensitivity analysis. The estimated input
data for the continuous ACRmodel based onmeanACR is
summarised in Table 3.
Efficacy Results
The models calculate the relative efficacy among all anti-
TNF agents and placebo. Relative efficacy for the con-
tinuous measures (HAQ improvement and ACRcont)
was measured as difference in improvement. Relative
improvement was modelled as a multiplier to baseline
HAQ score. Odds ratios were calculated for the bino-
mial measures ACR 20, ACR 50, ACR 70 and HAQ 20
and HAQ50. Thirteen trials were included for the HAQ
analysis and sixteen for the ACR analysis.
The MTC results are summarised in forest plots; in
Figure 5 for the HAQ measures and in Figure 6 for the
ACR measures. Binomial results are plotted on the log
scale. Plots showmean and 80% credible intervals to sum-
marize the posterior distribution for the relative efficay
between anti-TNF agents; significant differences on the
80% level are marked in red. The 80% level was chosen to
shift away from the misunderstood acceptance-rejection
dichotomy of random signifiance levels [23]. For addi-
tional information, Tables 5 and 6 provide the exact means
and interval endpoints; significant differences on the 80%
level are marked with a “∗”.
The key point is that all differences between agents
detected by the binary HAQ measures are also detected
by the continuous HAQ improvement measure, while not
all differences detected in the continuous HAQ model
are detected using the binary HAQ data; the differ-
ences detected by the binary HAQ measures are sub-
sets of the differences detected by the continuous HAQ
improvement measure. This is also demonstrated in the
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Figure 5 Forest Plot of HAQ results. Plots pairwise LORs for HAQ 20 and HAQ 50 outcome and improvement differences for % improvement in
HAQ score of anti-TNF agents against placebo and one another. Red colour indicates significant differences at the 80% level.
ACR analysis. It illustrates the point made that a contin-
uous measure of effect has a greater power to detect a
difference between treatments in an evidence synthesis.
Conclusion
This analysis illustrates the enhanced sensitivity to change
of continuous measures in MTC models compared to
using binary outcome measures, which was recently high-
lighted for epidemiological studies [48]. While binary
measures work well for demonstrating a certain level of
response, which is the primary aim of many clinical tri-
als, the information lost when categorizing the underlying
continuous response can have significant impact on the
results of a mixed treatment comparison.
MTCmodels are often utilized when faced with a choice
of agents rather than for demonstrating efficacy. In the
above application, for example, it is already known that
all of the anti-TNF agents provide improvement in the
treatment of RA. What remains is to determine whether
some of these agents work better than others. Therefore
Figure 6 Forest Plot of ACR results. Plots pairwise LORs for ACR 20, ACR 50 and ACR 70 outcome and improvement differences for ACRcont of
anti-TNF agents against placebo and one another. Red colour indicates significant differences at the 80% level.
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Table 5 Results fromHAQ analysis: Mean estimate with
80% credible intervals for each pair-wise comparison
Comparison HAQ HAQ20 HAQ50
Ada vs P 0.20 (0.17,0.23)* 2.6 (2.2,3.1)* 3.1 (2.1,4.4)*
Inf vs P 0.10 (0.06,0.15)* 1.6 (1.2,2.1)* 2.0 (1.2,3.5)*
Eta vs P 0.31 (0.25,0.37)* 3.6 (2.6,5.2)* 4.1 (2.2,7.7)*
Gol vs P 0.23 (0.17,0.29)* 2.8 (2.0,4.1)* 4.2 (1.9,8.8)*
Cert vs P 0.25 (0.22,0.29)* 3.3 (2.7,4.0)* 5.0 (3.0,7.6)*
Inf vs Ada -0.10 (-0.15,-0.05)* 0.6 (0.4,0.8)* 0.7 (0.3,1.3)
Eta vs Ada 0.11 (0.04,0.17)* 1.4 (0.9,2.1) 1.3 (0.7,2.7)
Eta vs Inf 0.21 (0.13,0.28)* 2.3 (1.4,3.6)* 2.0 (0.9,4.9)
Gol vs Ada 0.02 (-0.05,0.08) 1.1 (0.7,1.6) 1.4 (0.6,3.3)
Gol vs Inf 0.12 (0.05,0.20)* 1.8 (1.1,2.8)* 2.1 (0.8,5.4)
Gol vs Eta -0.09 (-0.17,0.00)* 0.8 (0.5,1.3) 1.0 (0.4,2.7)
Cert vs Ada 0.05 (0.00,0.09)* 1.2 (0.97,1.6) 1.6 (0.8,2.8)
Cert vs Inf 0.15 (0.10,0.21)* 2.0 (1.5,2.9)* 2.4 (1.1,4.7)*
Cert vs Eta -0.06 (-0.13,0.01) 0.9 (0.6,1.3) 1.2 (0.5,2.5)
Cert vs Gol 0.03 (-0.04,0.09) 1.1 (0.8,1.7) 1.2 (0.4,2.7)
σ 0.03 (0.01,0.05) 0.1 (0.0,0.3) 0.4 (0.1,0.6)
Significant results are marked with ∗. Outcomemeasures are % improvement for
continuous HAQ and ORs for HAQ 20 and HAQ 50. Ada=adalimumab;
Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo,
σ=between trial SD.
it would be of interest to know whether an agent provides
a 30% improvement or a 60% improvement. When look-
ing at the ACR 20 outcome, no difference would be seen
between the two response rates.
The above analyses have shown two things. Firstly, the
enhanced power to detect differences of a continuous
measure as opposed to a binary measure was shown for
both, the HAQ and the ACR measures. Secondly, the
choice of cut-off level (e.g. 20%, 50% or 70%) has shown to
have a strong impact on the results. Different significant
results were detected when choosing different cut-offs;
even the sequence of treatments when ordering from best
to worse changes.
It may be argued that binary outcomes are clear and
easy to interpret. However, where binary outcome mea-
sures are required, results based on continuous mea-
sures can be transformed subsequently using cut-off
points, [49].
From a clinical point of view these results show that a
MTCmodel based on continuous outcome measures pro-
vides greater precision of estimates of efficacy. This is of
great benefit when carrying out an economic evaluation.
Sensitivity Analysis
The trials included for the analysis were conducted over
a time period of 10 years. The model was extended to a
meta-regression to include potential confounding param-
eters such as duration of disease, number of previous
Table 6 Results from ACR analysis: Mean estimate with 80% credible intervals for each pair-wise comparison
Comparison ACR 20 ACR 50 ACR 70 ACRcont
Ada vs P 4.2 (3.4,5.3)* 5.6 (4.3,7.2)* 7.0 (4.3,10.9)* 0.27 (0.25,0.29)*
Inf vs P 3.5 (2.8,4.4)* 3.4 (2.7,4.4)* 3.7 (2.3,5.5)* 0.24 (0.22,0.27)*
Eta vs P 8.8 (5.5,13.9)* 12.1 (5.7,23.2)* 30.9 (4.2,123.8)* 0.32 (0.28,0.35)*
Gol vs P 3.3 (2.3,4.8)* 4.2 (2.7,6.5)* 6.5 (2.8,13.3)* 0.25 (0.21,0.28)*
Cert vs P 10.6 (8.0,14.1)* 9.5 (6.7,13.5)* 14.3 (6.8,27.0)* 0.32 (0.30,0.35)*
Inf vs Ada 0.8 (0.6,1.1) 0.6 (0.4,0.9)* 0.5 (0.3,1.0)* -0.03 (-0.06,0.00)*
Eta vs Ada 2.1 (1.2,3.4)* 2.2 (0.96,4.2) 4.4 (0.6,19.0) 0.05 (0.01,0.09)*
Eta vs Inf 2.5 (1.5,4.1)* 3.5 (1.5,6.9)* 8.3 (1.1,37.7)* 0.08 (0.03,0.12)*
Gol vs Ada 0.8 (0.5,1.2) 0.8 (0.4,1.2) 0.9 (0.4,2.2) -0.02 (-0.06,0.02)
Gol vs Inf 0.9 (0.6,1.5) 1.2 (0.7,2.0) 1.7 (0.7,4.1) 0.01 (-0.04,0.05)
Gol vs Eta 0.4 (0.2,0.7)* 0.3 (0.2,0.8)* 0.2 (0.0,1.8) -0.07 (-0.12,-0.02)*
Cert vs Ada 2.5 (1.8,3.6)* 1.7 (1.1,2.6)* 2.1 (0.9,4.7) 0.05 (0.02,0.09)*
Cert vs Inf 3.0 (2.1,4.3)* 2.8 (1.8,4.3)* 3.8 (1.7,8.3)* 0.08 (0.05,0.12)*
Cert vs Eta 1.2 (0.7,2.0) 0.8 (0.4,1.8) 0.5 (0.1,3.6) 0.01 (-0.04,0.05)
Cert vs Gol 3.2 (2.0,5.1)* 2.3 (1.3,3.9)* 2.2 (0.8,6.4) 0.08 (0.03,0.12)*
σ 0.2 (0.0,0.4) 0.2 (0.0,0.4) 0.5 (0.0,0.8) 0.03 (0.01,0.04)
Significant results are marked with ∗. Outcome measures are ORs for ACR 20, ACR 50 and ACR 70 and % improvement for ACRcont. Ada=adalimumab; Inf=infliximab;
Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo, σ=between trial SD.
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DMARDs and year of publication. None of these were
found to have a significant impact and therefore were not
included in the main analysis.
Different prior distributions on the between trial vari-
ance parameter allowing for a wider range of values were
tested, but did not alter the conclusions. Varying the pre-
cision parameter of the normal prior distributions for the
remaining parameters between 1,000 and 100,000 did not
alter the results either.
The continuous ACR response underlying the binary
ACR 20, ACR 50 and ACR 70 measures is estimated using
the mean ACRcont response for each of the four respon-
der groups. For the baseline analysis meanACR was used
as the underlying continuous effect. In a sensitivity analy-
sis a model was fit using the ACR hybrid as the underlying
effect. This did not alter the results much, however, adal-
imumab was not found to be superior to infliximab in
this scenario. There was substantial uncertainty regard-
ing the mean ACRcont response in the control arms, as
no patient level data was available. An additional model
has been fit assuming the mean response in each group
to be the same for treatment arms and control arms.
While this did influence the biologic treatment effect
versus control, the relative efficacy between biologic treat-
ments was not affected much. Again, these models did
not detect a difference between adalimumab and inflix-
imab. Outcomes of the various MTCs can be accessed in
Additional file 3.
The scale chosen for dichotomized outcome measures
has been shown to influence outcomes of MTC models
[50]. In addition to the OR scale we therefore also fitted an
analysis based on risk ratios (RRs). The OR model can be
adapted to estimate RRs making a few changes, for further
details see Schmitz et al. [23]. The results can be accessed
in Additional file 4; the findings of increased power of
continuous outcomes are confirmed.
Limitation
Doses across treatments and treatment arms varied,
which has not been accounted for in the analysis. Gen-
eralising the model to include a meta-regression for dose
would raise difficulties of comparability; doses across
treatments are hard to compare as well as within one
treatment when the same dose is given, but with different
frequency.
The analysis only includes RCT evidence. However,
there exists a large body of observational data collected
via registries and open label studies. The inclusion of such
evidence is possible within this framework, helping to
reduce uncertainty further [51].
Patient level data allowed the estimation of mean ACR
response within each of the responder groups. While this
provided some additional information towards estimating
the continuous ACR response measure, it did not replace
the full information lost. The estimated ACRcont mea-
sure is still subject to high uncertainty. Patient level data
of the RCTs included in the analysis would allow the exact
calculation of the continuous ACR measure.
The evidence network has a star design, which
does not allow testing of the assumption of treatment
exchangeability. Baseline characteristics across the tri-
als were compared and and the model was extended to
a meta-regression to explain the potential influence of
differing demographics.
This paper confirms the effectiveness of anti-TNF
agents in the treatment of RA. The study illustrates the
enhanced ability to detect differences between treatments
when using continuous measures and shows the high
dependency of MTC outcomes on the cut-off level when
using binary data.
Rather than steering away from binary measures, we
would like to advocate the additional reporting of under-
lying continuous effect measures in clinical trials to facil-
itate further analyses. The importance of the involvement
of statisticians in the choice of clinical measures has been
recently highlighted [10].
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